CN Patent

CN112969700B — 作为α4β7整合素抑制剂的咪唑并吡啶衍生物

Assigned to Gilead Sciences Inc · Expires 2024-08-20 · 2y expired

What this patent protects

本公开提供了如本文描述的式(I)化合物或其药学上可接受的盐。本公开还提供了包含式(I)化合物的药物组合物，式(I)化合物的制备方法，以及炎性疾病的治疗方法。

USPTO Abstract

本公开提供了如本文描述的式(I)化合物或其药学上可接受的盐。本公开还提供了包含式(I)化合物的药物组合物，式(I)化合物的制备方法，以及炎性疾病的治疗方法。

Drugs covered by this patent

momelotinib-dihydrochloride (MOMELOTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN112969700B
Jurisdiction: CN
Classification: —
Expires: 2024-08-20
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.